Background: Thromboembolic disease is a major cause of morbidity and mortality in many countries. Our previous study found that Chinese subjects carried the same polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene as described in Western studies. The aim of the present study was to determine the influence of MTHFR polymorphism, B vitamins and other factors on plasma homocysteine (Hcy) levels and risk of thromboembolic disease in Chinese. Methods: One hundred and six subjects were enrolled into the study. They were categorized into 4 groups: healthy individuals (n = 42); those with diabetes mellitus (n = 20); those with deep vein thrombosis (DVT) (n = 11); and those with coronary artery disease (CAD) (n = 33). Plasma levels of folic acid, vitamins B6 and B12, Hcy, and fasting blood sugar were measured; total cholesterol, triglycerides, complete blood count, and 677 C→T mutation in MTHFR were determined. Results: Plasma Hcy was lowest in the healthy subjects, higher in diabetics, followed by patients with DVT, and highest in patients with CAD (p < 0.001, ANOVA). MTHFR C677T polymorphism was the common factor affecting plasma logHcy levels in all 4 groups of subjects. Triglycerides affected plasma logHcy in the CAD patients. For the 4 groups as a whole, MTHFR polymorphism, triglycerides, and vitamin B12 were the most significant factors influencing plasma Hcy. Conclusion: We suggest that high plasma Hcy is an important risk factor for CAD. Other factors including MTHFR polymorphism, vitamin B12, triglycerides, total cholesterol, and gender might affect Hcy levels in different diseases and conditions. [J Chin Med Assoc 2005;68(12):560-565] 
Introduction
Thromboembolic disease remains a major cause of morbidity and mortality in many countries. Since 1993, factor V Leiden and PT20210 A allele have been found to be the major causes of thromboembolic disease in the West. However, Chinese people are less prone to thromboembolic disease. [1] [2] [3] While our recent studies in Chinese populations found neither factor V Leiden nor PT20210 A allele, [4] [5] [6] we did find that the Chinese carried the same methylenetetrahydrofolate reductase (MTHFR) gene polymorphism as described in Western studies, 6 with the C→T substitution at nucleotide 677 being another possible cause of thrombosis. Whether or not this polymorphism can affect homocysteine (Hcy) levels in Chinese patients deserves our investigation. The present study was, thus, conducted to determine the influence of MTHFR gene polymorphism, B vitamins and other possible factors on plasma Hcy levels and risk of thromboembolic disease in Chinese.
Methods
A total of 106 subjects were enrolled into the study and divided into 4 groups. Group A comprised healthy subjects without a history of diabetes mellitus (DM), thromboembolic disease, or of taking any medication in the previous 2 weeks. Group B included patients with type 2 DM with normal renal function. Group C had patients with deep vein thrombosis (DVT) as shown on sonogram. Group D included patients with coronary artery disease (CAD) as shown on angiogram, with at least 1 major vessel having more than 75% stenosis.
After signed informed consent was obtained from each subject, blood samples were taken (between 9 and 10 a.m.) after a 12-hour fast, and not at the acute stage for patients with DVT, in order to test for MTHFR gene mutations, and to measure plasma Hcy levels, complete blood count, total cholesterol, triglycerides, fasting blood sugar (FBS), and vitamin B6, vitamin B12 and folate levels.
DNA analysis for the MTHFR 677C→T polymorphism was performed using the methods described by Frosst et al. 7 DNA was extracted from the buffy coat of the collected peripheral blood as previously described 7 and approximately 0.5 µg was used for amplification by the polymerase chain reaction (PCR). The DNA samples were stored at 4°C for not more than 12 months before they were analyzed.
To detect the 677C→T transition in the MTHFR gene, PCR was performed with 5 ρM of forward and reverse primers 7 Complete blood count was measured with an automated hematology analyzer (Sysmex SE9000, Toa Medical Electronics Co Ltd, Kobe, Japan). Total cholesterol, triglycerides and FBS were determined with the SMAC-II Analyzer (Technicon Corp, Tarrytown, NY, USA).
ANOVA and the Chi-squared test were used to check the statistical significance of trends among parameters. The Scheffe test was used for multiple comparison if ANOVA results were significant. Multivariate linear regression was used to detect the effect of logHcy levels after adjusting for other variables. As plasma Hcy levels were known to be not normally distributed, we used the KolmogorovSmirnov method to test whether logHcy or the square root of Hcy was better at representing Hcy. The results showed that logHcy represented Hcy levels best, although Hcy, logHcy and the square root of Hcy were not normally distributed. Thus, we used logHcy instead of Hcy.
Results
Of the 106 subjects, 42 were in Group A (healthy), 20 in Group B (type 2 DM), 11 in Group C (DVT), and 33 in Group D (CAD). The mean ages in groups A, B, C, and D were 64.9 ± 5.4 years (range, 60-78 years), 64.3 ± 15.0 years (range, 35-86 years), 63.5 ± 13.9 years (range, 40-83 years), and 69.3 ± 11.4 years (range, 33-85 years), respectively. Table 1 shows the various parameters in the 4 groups. FBS, Hcy and gender were significantly different among the 4 groups, based on ANOVA (p < 0.001, p < 0.001, p = 0.016, respectively). Plasma Hcy was lowest in the healthy subjects, higher in diabetics, followed by patients with DVT, and highest in patients with CAD. Differences were significant between healthy subjects and CAD patients, and between DM and CAD patients, based on the Scheffe test (p < 0.001, p = 0.002, respectively) ( Table 2 ). There was a greater proportion of males in Group D (CAD) than in Group A (healthy) (p = 0.016). On the other hand, there was no significant difference among the groups regarding MTHFR 677TT and MTHFR 677CT polymorphism (p = 0.580, p = 0.964, respectively).
Differences in the various parameters

Influence of the various parameters and MTHFR mutations on plasma Hcy
Multivariate analysis showed that MTHFR-all could affect plasma logHcy levels in all 4 groups (p < 0.005, Table 3 ), MTHFR-TT polymorphism and triglycerides could affect plasma logHcy level in the CAD patients (p = 0.005, p = 0.006, respectively). Putting all groups together, we found that triglycerides and vitamin B12 could affect logHcy level (p < 0.005, p = 0.026, respectively). Multivariate analysis, using the stepwise method, showed that triglycerides had the highest degree of influence on logHcy in the healthy. The most influential factors were cholesterol in the diabetics and triglycerides and MTHFR-TT polymorphism in the CAD group. Putting all groups together, the weight of effect was in order of triglycerides, MTHFR-TT and vitamin B12 (Table 4) .
Discussion
Thromboembolic disease occurs less frequently in Chinese than in Caucasians. [1] [2] [3] During the past few years, much effort has been made to better understand the causes of idiopathic venous thrombosis, i.e. the discovery of factor V Leiden, PT20210A allele and MTHFR gene polymorphism. [7] [8] [9] [10] [11] [12] [13] [14] Although factor V Leiden and PT20210A allele have been found to be the most frequent causes of thromboembolic disease in the West, they are absent in the Chinese. [4] [5] [6] 15 However, MTHFR C677T polymorphism can be found in Chinese subjects. 6 MTHFR polymorphism itself is not a risk factor of thromboembolic disease, but high plasma levels of the amino acid Hcy are. 16 One of the main functions of MTHFR is remethylation of Hcy into methionine. 17 A common MTHFR polymorphism, an alanine-to-valine substitution, renders the enzyme thermolabile, elevating plasma levels of Hcy, 18 which increases the risk of occlusive vascular disease. 19 However, in addition to genetic factors, plasma Hcy levels can also be influenced by environmental factors such as folate, and vitamins B6 and B12. [20] [21] [22] Although the sample size in the present study was not large, this is 1 of the few studies on Chinese subjects. The influence of genetic and environmental factors on Hcy levels was compared in 4 groups representing different degrees of risk for thromboembolic disease in Chinese.
We found that plasma Hcy was lowest in the healthy subjects, higher in diabetics, followed by patients with DVT, and highest in patients with CAD ( Table 1 ). The Scheffe test showed significantly higher plasma Hcy in CAD patients than in DM patients and healthy subjects (Table 2 ). However, there was no significant difference in the percentage of MTHFR C677T polymorphism, either -CT or -TT, among the 4 groups. This demonstrated that MTHFR poly- The order of influence = Model 1 > Model 2 > Model 3. *MTHFR-all = homologous + heterologous polymorphism and MTHFR-TT = homologous polymorphism. CAD = coronary artery disease; DM = diabetes mellitus; DVT = deep vein thrombosis; Hcy = homocysteine; MTHFR = methylenetetrahydrofolate reductase gene.
morphism itself was not a risk factor for thromboembolic disease, but plasma Hcy level was. The cause of this discrepancy in the influence of MTHFR polymorphism and plasma Hcy in our study is not known; perhaps the small sample size or other unknown factors played a role. Further studies with a larger sample size should be performed to obtain clearer conclusions.
Although there was no significant difference in the percentages of MTHFR polymorphism among the 4 groups, on multivariate analysis, we found that MTHFR polymorphism affected the logHcy level in all 4 groups ( Table 3) . MTHFR 677TT polymorphism affected the logHcy level in CAD patients, and MTHFR 677CT polymorphism affected Group A (healthy) and all groups combined (A+B+C+D). Thus, MTHFR seemed to be able to affect plasma Hcy levels in the different groups of subjects in our study. Vitamin B12 affected plasma Hcy in all groups of subjects, and triglycerides affected logHcy in CAD patients and all groups combined (p = 0.006 and p < 0.0005, respectively). This demonstrated that plasma Hcy levels were affected by multiple factors.
Males usually have higher plasma Hcy; 23 male gender is a well-known risk factor for CAD, and this was also shown in our study (Table 2) . On the other hand, since the status of male gender did not affect DVT, there must be multiple influences leading to DVT, and plasma Hcy probably plays a less important role in the cause of DVT.
From the present preliminary study, we conclude that plasma Hcy level is a risk factor for CAD. Many factors including MTHFR polymorphism, vitamin B12, triglycerides, gender and total cholesterol might affect Hcy levels in different diseases and conditions.
